Troluce Capital Advisors LLC Cytokinetics Inc Transaction History
Troluce Capital Advisors LLC
- $592 Million
- Q1 2024
A detailed history of Troluce Capital Advisors LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Troluce Capital Advisors LLC holds 175,000 shares of CYTK stock, worth $9.8 Million. This represents 2.07% of its overall portfolio holdings.
Number of Shares
175,000Holding current value
$9.8 Million% of portfolio
2.07%Shares
0 transactions
Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
---|
Others Institutions Holding CYTK
# of Institutions
460Shares Held
108MCall Options Held
7.2MPut Options Held
6.2M-
Black Rock Inc. New York, NY12.4MShares$695 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$560 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.12MShares$287 Million0.22% of portfolio
-
Bank Of America Corp Charlotte, NC4.78MShares$267 Million0.03% of portfolio
-
State Street Corp Boston, MA4.52MShares$253 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.27B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...